Cencora (NYSE:COR) PT Raised to $224.00

Cencora (NYSE:CORGet Free Report) had its price target increased by equities researchers at Mizuho from $192.00 to $224.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Mizuho’s target price would indicate a potential downside of 4.64% from the stock’s current price.

Several other research analysts also recently issued reports on COR. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. TheStreet raised Cencora from a “c” rating to a “b” rating in a research note on Monday, October 9th. Wells Fargo & Company assumed coverage on Cencora in a research note on Thursday, December 14th. They set an “equal weight” rating and a $213.00 target price for the company. Barclays assumed coverage on Cencora in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $242.00 target price for the company. Finally, Evercore ISI upped their price target on Cencora from $210.00 to $225.00 in a research report on Wednesday, October 11th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $209.78.

View Our Latest Analysis on COR

Cencora Trading Up 0.3 %

Shares of Cencora stock opened at $234.91 on Monday. The firm has a market capitalization of $47.15 billion, a PE ratio of 25.59, a price-to-earnings-growth ratio of 2.01 and a beta of 0.45. The company has a debt-to-equity ratio of 3.94, a current ratio of 0.88 and a quick ratio of 0.52. The company’s fifty day moving average price is $211.60 and its two-hundred day moving average price is $196.74. Cencora has a 52-week low of $147.48 and a 52-week high of $237.67.

Cencora (NYSE:CORGet Free Report) last issued its earnings results on Wednesday, January 31st. The company reported $3.28 EPS for the quarter, beating the consensus estimate of $2.86 by $0.42. Cencora had a net margin of 0.69% and a return on equity of 323.23%. The company had revenue of $72.25 billion for the quarter, compared to the consensus estimate of $68.81 billion. During the same quarter in the previous year, the company earned $2.71 EPS. On average, analysts expect that Cencora will post 13.43 EPS for the current year.

Insider Buying and Selling at Cencora

In related news, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $203.60, for a total value of $407,200.00. Following the transaction, the chief accounting officer now owns 19,876 shares in the company, valued at $4,046,753.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $203.60, for a total value of $407,200.00. Following the transaction, the chief accounting officer now owns 19,876 shares in the company, valued at $4,046,753.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Walgreens Boots Alliance, Inc. sold 1,279,590 shares of Cencora stock in a transaction dated Thursday, November 9th. The shares were sold at an average price of $195.38, for a total value of $250,006,294.20. Following the completion of the transaction, the insider now owns 30,489,956 shares in the company, valued at approximately $5,957,127,603.28. The disclosure for this sale can be found here. Insiders sold 1,338,377 shares of company stock valued at $261,764,507 in the last quarter. 15.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cencora

A number of hedge funds and other institutional investors have recently made changes to their positions in COR. Harbour Investments Inc. increased its holdings in shares of Cencora by 61.8% during the first quarter. Harbour Investments Inc. now owns 165 shares of the company’s stock valued at $26,000 after acquiring an additional 63 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its position in Cencora by 50.9% in the second quarter. Creative Financial Designs Inc. ADV now owns 175 shares of the company’s stock worth $34,000 after purchasing an additional 59 shares during the last quarter. MBM Wealth Consultants LLC purchased a new position in Cencora in the fourth quarter worth $41,000. KB Financial Partners LLC purchased a new position in shares of Cencora during the 1st quarter valued at $42,000. Finally, Sunbelt Securities Inc. purchased a new position in shares of Cencora during the 1st quarter valued at $44,000. 93.12% of the stock is owned by institutional investors and hedge funds.

About Cencora

(Get Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Further Reading

Analyst Recommendations for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.